Preclinical studies in HCC to target this pathway include oral inhibitors of MEK, a key enzyme in the Ras-Raf-MEK-extracellular signal regulated kinase (ERK) kinase pathway, which is constitutively active in variety of solid tumors. The gene discussed is RAF1; the disease is hepatocellular carcinoma.